Pulmonary arterial hypertension from a pediatric perspective

Pediatric and Developmental Pathology

Volumn 11, Issue 3, 2008, Pages 169-177

  Cool, Carlyne D ^a,b   Deutsch, Gail ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Congenital heart disease; Pediatric pulmonary hypertension; Persistent pulmonary hypertension of the newborn

Indexed keywords

ALTITUDE; ARTICLE; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLLAGEN DISEASE; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FAMILIAL DISEASE; GAUCHER DISEASE; GENETIC SUSCEPTIBILITY; GLYCOGEN STORAGE DISEASE; HEMOGLOBINOPATHY; HEREDITARY HYPERTENSION; HIGH RISK PATIENT; HISTIOCYTOSIS X; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXEMIA; IDIOPATHIC DISEASE; INFECTION RISK; INTERSTITIAL LUNG DISEASE; LONG TERM EXPOSURE; LUNG ALVEOLUS HYPOVENTILATION; LUNG EMBOLISM; LYMPHADENOPATHY; LYMPHANGIOMATOSIS; MEDIASTINITIS; MYELOPROLIFERATIVE DISORDER; NEWBORN DISEASE; PERSISTENT PULMONARY HYPERTENSION; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; RENDU OSLER WEBER DISEASE; SARCOIDOSIS; SLEEP DISORDERED BREATHING; SPLENECTOMY; THROMBOEMBOLISM; VASCULAR LESION; VIRUS PATHOGENESIS; WORLD HEALTH ORGANIZATION;

CHILD; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE;

EID: 48849095189     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.2350/07-12-0398.1     Document Type: Article

References (76)

1. Romberg E. Uebere Sklerose der Lungenarterien. Dtsch Arch Klin Med 1891;48:197-206.
2. Eisenmenger V Die angeborenen Defekte der Kammerscheidewände des Herzens. Zeitschr Klin Med 1897;32(suppl):1-28.
3. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958;20:557-570.
4. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18:533-547.
5. Palevsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989;80:1207-1221.
6. Haworth SG, Rabinovitch M, Meyrick B, et al. Primary pulmonary hypertension: executive summary from the World Symposium on Primary Pulmonary Hypertension. In: Rich S, ed. Evian, France: World Health Organization, 1998;2-5.
7. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol 2004;43(suppl 12):1S-90S.
8. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-285.
9. Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-419.
10. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000;162:1577-1586.
11. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 1998;114(suppl 3):225S-230S.
12. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998;101:927-934.
13. Yeager ME, Golpon HA, Voelkel NF, Tuder RM. Microsatellite mutational analysis of endothelial cells within plexiform lesions from patients with familial, pediatric, and sporadic pulmonary hypertension. Chest 2002;121(suppl 3):61S.
14. Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 2003;92:1162-1169.
15. McMurtry MS, Archer SL, Altieri DC, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115: 1479-1491.
16. Tuder RM, Cool CD, Yeager ME, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium 2001;22:405-418.
17. Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. Am J Pathol 2001;195:367-374.
18. Deuthsch GH, Davie NJ, Serls AE, Cool CD, Stenmark KR. Aberrant adventitial changes in a subset of cases with secondary pediatric pulmonary hypertension. Society for Pediatric Pathology Annual Meeting (poster), Washington, D.C. Laboratory Investigation, 2003; 83.
19. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107:216-223.
20. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Vascular endothelial growth factor receptor blockade by SU5416 combined with pulsatile shear stress causes apoptosis and subsequent proliferation of apoptosis-resistant endothelial cells. Chest 2005; 128(suppl 6):610S-611S.
21. White RJ, Galaria II, Harvey J, Blaxall BC, Cool CD, Taubman MB. Tissue factor is induced in a rodent model of severe pulmonary hypertension characterized by neointimal lesions typical of human disease. Chest 2005;128(suppl 6):612S-613S.
22. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-q32. Nat Genet 1997;15:277-280.
23. Morse JH, Jones AC, Barst RJ, et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997;95:2603-2606.
24. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67: 737-744.
25. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension: The International PPH Consortium. Nat Genet 2000;26:81-84.
26. Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319-324.
27. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37:741-745.
28. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006;27:121-132.
29. Harrison RE, Berger R, Haworth SG, et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005;111:435-441.
30. Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003;40:865-871.
31. Langston C. Misalignment of pulmonary veins and alveolar capillary dysplasia. Pediatr Dev Pathol 2000;3:271-276.
32. Alameh J, Bachiri A, Devisme L, et al. Alveolar capillary dysplasia: a cause of persistent pulmonary hypertension of the newborn. Eur J Pediatr 2002;161:262-266.
33. Tibballs J, Chow CW. Incidence of alveolar capillary dysplasia in severe idiopathic persistent pulmonary hypertension of the newborn. J Pediatr Child Health 2002;38:397-400.
34. Sen P, Thakur N, Stockton D, Langston C, Bejjani B. Expanding the phenotype of alveolar capillary dysplasia (ACD). J Pediatr 2004;145: 646-651.
35. Juaneda E, Haworth SG. Pulmonary vascular disease in children with truncus arteriosus. Am J Cardiol 1984;54:1314-1320.
36. Reid JM, Stevenson JG, Coleman EN, et al. Moderate to severe pulmonary hypertension accompanying patent ductus arteriosus. Br Heart J 1964;26:600-605.
37. Conklin BS, Zhong DS, Zhao W, Lin PH, Chen C. Shear stress regulates occludin and VEGF expression in porcine arterial endothelial cells. J Surg Res 2002;102:13-21.
38. Lévy L, Maurey C, Celermajer D, et al. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 2007;49:803-810.
39. Ungerer RG, Tahskin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74.
40. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-524.
41. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-1093.
42. Salerni R, Rodnan GP, Leon DF, et al. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977;86:394-399.
43. Humbert M, Sanchez O, Fartoukh M, et al. Treatment of severe pulmonary hypertension secondary to connective tissue disease with continuous IV epoprostenol (prostacyclin). Chest 1998; 114(suppl):80S-82S.
44. Sullivan WD, Hurst DJ, Harmon CE, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine 1984;63:92-107.
45. Wigley F, Lima J, Mayes M, McLain D, Chapin L, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-2132.
46. Gardner DL, Duthie JR, MacLeod J, Allen WSH. Pulmonary hypertension in RA: report of a case study with intimal sclerosis of pulmonary and digital arteries. Scott Med J 1957;2:183-186.
47. Helmers R, Galvin J, Hunninghake GW. Pulmonary manifestations associated with rheumatoid arthritis. Chest 1991;100:235-238.
48. Simonson JS, Schiller NB, Petri M, Hellmann DB. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989;16: 918-925.
49. Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience within twenty four patients. J Rheumatol 1990;17:1292-1298.
50. Perez HD, Kramer N. Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum 1981;11:77-181.
51. Quismorio FP, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984;13:349-359.
52. Nishimaki T, Aotsuka S, Kondo H. et al. Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 1999;26:2357-2362.
53. Alarcon-Segovia D, Eeleze M, Oria CV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine 1989;68: 353-365.
54. Asherson RA, Hackett D, Gharavi AE, Harris EN, Kennedy HG, Hughes GR. Pulmonary hypertension in systemic lupus erythematosus: a report of three cases. J Rheumatol 1986;13:416-420.
55. Asherson RA, Cervera R. Review: antiphospholipid antibodies and the lung. J Rheumatol 1995;22:62-66.
56. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and HIV infection. Hum Pathol 1997;28:434-442.
57. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest 2003;123:562-576.
58. Ramsay MA, Simpson BR, Nguyet AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3:494-500.
59. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17:17-33.
60. Flemale A, Sabot JP, Popijn M, et al. Pulmonary hypertension associated with portal thrombosis. Eur J Respir Dis 1985;66:224-228.
61. Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1156.
62. Bernardi M, Gulberg V, Colantoni A, et al. Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol 1996;24:161-168.
63. Gerbes Al, Moller S, Gulberg V, et al. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735-739.
64. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774-1748.
65. Hoepe MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363:1461-1468.
66. Condino AA, Ivy DD, O'Connor JA, et al. Portopulmonary hypertension in pediatric patients. J Pediatr 2005;147:20-26.
67. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-1271.
68. Pongprot Y, Sittiwangkul R, Silvilairat S, et al. Cardiac manifestations in HIV-infected Thai children. Ann Trop Paediatr 2004;24:153-159.
69. Marecki JC, Cool CD, Parr JE, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected Macaques. Am J Respir Crit Care Med 2006;174:437-445.
70. Bull TM, Cool CD, Serls AE, et al. Primary pulmonary hypertension, Castleman's disease and HHV-8. Eur Respir J 2003;22:403-407.
71. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. New Engl J Med 2003;349: 1113-1122.
72. Laney AS, De M, Peters JS, et al. Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest 2005;127:762-767.
73. Katano H, Ito K, Shibuya K, et al. Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension. J Infect Dis 2001;191:743-745.
74. Nicastri E, Vizza CD, Carletti F, et al. Human herpesvirus 8 and pulmonary hypertension. Emerg Infect Dis 2005;11:1480-1482.
75. Henke-Gendo C, Mengel M, Hoeper MM, et al. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 1915;172:1581-1585.
76. Galambos C, Montgomery J, Jenkins FJ. No role for kaposi sarcoma-associated herpesvirus in pediatric idiopathic pulmonary hypertension. Pediatr Pulmonol 2006;41:122-125.